Which is the best statin for the postoperative coronary artery bypass graft patient?
| Autor: | Allan M. Conway, Ghassan Musleh |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Statin medicine.drug_class Atorvastatin Drug Costs Coronary Restenosis chemistry.chemical_compound Coronary artery bypass surgery Internal medicine medicine Humans Rosuvastatin cardiovascular diseases Coronary Artery Bypass Aged Postoperative Care business.industry Cholesterol nutritional and metabolic diseases Cholesterol LDL General Medicine Middle Aged Drug Utilization Tolerability chemistry Simvastatin Cardiology Female lipids (amino acids peptides and proteins) Surgery Observational study Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | European Journal of Cardio-Thoracic Surgery. 36:628-632 |
| ISSN: | 1010-7940 |
| DOI: | 10.1016/j.ejcts.2009.03.064 |
| Popis: | The progression of atherosclerosis following coronary artery bypass graft (CABG) surgery results in the need for re-vascularisation therapy in a significant proportion of patients. It is well recognised that this risk can be lowered by controlling the level of low-density lipid cholesterol (LDL-C) which can be achieved easily and safely with the use of statins. The choice of which is the best statin in post-CABG patients remains unclear. It has been shown that for milligram-equivalent doses, rosuvastatin provides the greatest LDL-C reduction and greatest number of patients achieving LDL-C targets in comparison with simvastatin and atorvastatin. Rosuvastatin's superiority over other statins in allowing patients to reach LDL-C targets has been maintained in 'real-world' observational studies. Rosuvastatin has also been shown to increase high-density lipid cholesterol (HDL-C) by greater proportions in comparison with other statins, providing increased anti-atherogenic effects. There are several statins currently available, some of which are now generic. However, the empirical use of generic statins does not necessarily translate into a cost-effective treatment option. This article reviews the rationale for lipid-lowering therapy in patients following CABG. We also look objectively at which is the best statin for use in the post-CABG patient, discussing effectiveness, cost and tolerability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|